FI973259A - Use of LCK-SH2-Specific Compounds in the Treatment of Autoimmune Diseases and Tissue Transplant Rejection - Google Patents
Use of LCK-SH2-Specific Compounds in the Treatment of Autoimmune Diseases and Tissue Transplant Rejection Download PDFInfo
- Publication number
- FI973259A FI973259A FI973259A FI973259A FI973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A FI 973259 A FI973259 A FI 973259A
- Authority
- FI
- Finland
- Prior art keywords
- lck
- treatment
- autoimmune diseases
- transplant rejection
- specific compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38638195A | 1995-02-10 | 1995-02-10 | |
| US40022095A | 1995-03-07 | 1995-03-07 | |
| US49735795A | 1995-06-30 | 1995-06-30 | |
| PCT/US1996/001964 WO1996024343A1 (en) | 1995-02-10 | 1996-02-09 | Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI973259A0 FI973259A0 (en) | 1997-08-07 |
| FI973259A true FI973259A (en) | 1997-10-08 |
Family
ID=27409758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973259A FI973259A (en) | 1995-02-10 | 1997-08-07 | Use of LCK-SH2-Specific Compounds in the Treatment of Autoimmune Diseases and Tissue Transplant Rejection |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0809490A4 (en) |
| JP (2) | JPH10513474A (en) |
| KR (1) | KR19980702115A (en) |
| AU (1) | AU4923796A (en) |
| BR (1) | BR9607614A (en) |
| CA (1) | CA2212645A1 (en) |
| FI (1) | FI973259A (en) |
| HU (1) | HUP9802078A3 (en) |
| NO (1) | NO973659L (en) |
| WO (1) | WO1996024343A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922697A (en) * | 1996-10-02 | 1999-07-13 | Warner-Lambert Company | Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins |
| RU2344128C2 (en) | 2003-03-24 | 2009-01-20 | Ф.Хоффманн-Ля Рош Аг | Benzylpyridazinones as inhibitors of reverse transcriptase |
| CN1934092A (en) | 2004-03-23 | 2007-03-21 | 弗·哈夫曼-拉罗切有限公司 | Non-nucleoside reverse transcriptase inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5136093A (en) * | 1992-09-25 | 1994-04-26 | Warner-Lambert Company | Peptide antagonists of sh2 binding and therapeutic uses thereof |
| US5580979A (en) * | 1994-03-15 | 1996-12-03 | Trustees Of Tufts University | Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions |
| US5710129A (en) * | 1995-02-23 | 1998-01-20 | Ariad Pharmaceuticals, Inc. | Inhibitors of SH2-mediated processes |
-
1996
- 1996-02-09 JP JP8524486A patent/JPH10513474A/en active Pending
- 1996-02-09 CA CA002212645A patent/CA2212645A1/en not_active Abandoned
- 1996-02-09 EP EP96905494A patent/EP0809490A4/en not_active Withdrawn
- 1996-02-09 BR BR9607614A patent/BR9607614A/en not_active Application Discontinuation
- 1996-02-09 HU HU9802078A patent/HUP9802078A3/en unknown
- 1996-02-09 KR KR1019970705510A patent/KR19980702115A/en not_active Application Discontinuation
- 1996-02-09 WO PCT/US1996/001964 patent/WO1996024343A1/en not_active Application Discontinuation
- 1996-02-09 AU AU49237/96A patent/AU4923796A/en not_active Abandoned
- 1996-02-12 JP JP8524493A patent/JPH10513564A/en active Pending
- 1996-02-12 EP EP96906615A patent/EP0811159A1/en not_active Withdrawn
-
1997
- 1997-08-07 FI FI973259A patent/FI973259A/en unknown
- 1997-08-08 NO NO973659A patent/NO973659L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10513474A (en) | 1998-12-22 |
| EP0809490A1 (en) | 1997-12-03 |
| EP0809490A4 (en) | 1999-10-20 |
| WO1996024343A1 (en) | 1996-08-15 |
| HUP9802078A2 (en) | 1998-12-28 |
| NO973659L (en) | 1997-10-08 |
| HUP9802078A3 (en) | 1999-04-28 |
| CA2212645A1 (en) | 1996-08-15 |
| BR9607614A (en) | 1998-06-09 |
| KR19980702115A (en) | 1998-07-15 |
| EP0811159A1 (en) | 1997-12-10 |
| AU4923796A (en) | 1996-08-27 |
| NO973659D0 (en) | 1997-08-08 |
| JPH10513564A (en) | 1998-12-22 |
| FI973259A0 (en) | 1997-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69117117D1 (en) | Cleaning composition for the prevention and alleviation of skin irritation | |
| ID17156A (en) | ANTI-COAGULAN SUBSTANCE USE IN TREATMENT OF TROMBOSIS | |
| EE03512B1 (en) | Epinastine for use in the treatment of pain | |
| DE69505657D1 (en) | FLUORCARBONETHERHYBRIDS CONTAINING PHYSIOLOGICALLY ACCEPTABLE EMULSIONS AND METHODS OF USE | |
| ATE349428T1 (en) | PROSTAGLAND INAGONISTS AND THEIR USE IN THE TREATMENT OF BONE DISEASES | |
| DE69838338D1 (en) | USE OF ANTIMYKOTICA FOR THE TOPIC TREATMENT OF MUSHROOM INDUCED TISSUE SKIN INJECTION | |
| DE69830728D1 (en) | MEDICAMENT FOR THE TREATMENT OF COMMON WATER AND HARN INCONTINENCE | |
| DE69600100D1 (en) | Powder puff for local treatment of the skin | |
| BR9406209A (en) | Heterocyclic derivatives in the treatment of ischemia and related diseases | |
| DE69635364D1 (en) | Blood filter and extracorporeal circulation | |
| DE69729817D1 (en) | Treatment of aldehyde-fixed tissues | |
| FI952656A0 (en) | Foerfarande and anordning vid pulsmaetning av en person | |
| FI965204A (en) | Medical use of bromelain | |
| ATE225662T1 (en) | USE OF INDIGESTIBLE OLIGOSACCHARIDES FOR PREVENTING AND TREATING MEDICINE EAR INFLAMMATION IN HUMAN BEINGS | |
| ID21948A (en) | USE OF 1-HYDROXY-2-PYRIDON FOR TREATMENT OF SKIN INFECTIONS | |
| DE69807466D1 (en) | TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| FI955786A (en) | Use of natural products and similar synthetic compounds in the treatment of cardiovascular diseases | |
| FR2751541B1 (en) | DERMO-COSMETIC COMPOSITION CONTAINING A QUINQUINA ALKALOID AND METHOD FOR THE COSMETIC TREATMENT OF ALOPECIA | |
| FI941345A (en) | Retinoids and their use in the treatment of skin diseases and leukemia | |
| ID21874A (en) | USE OF 1-HYDROXY-2-PYRIDON FOR TREATMENT OF SKIN INFECTION | |
| DE69822297D1 (en) | TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| DE69822276T2 (en) | HERBAL FORMULATION WITH THERAPEUTIC AND COSMETIC USE FOR THE TREATMENT OF GENERAL SKIN DISEASES | |
| FI973259A (en) | Use of LCK-SH2-Specific Compounds in the Treatment of Autoimmune Diseases and Tissue Transplant Rejection | |
| ZA971607B (en) | Methods of treatment of allergic diseases | |
| FI964113A0 (en) | Medical composition for the treatment of tardive dyskinesia and its use |